RMBS offers contract development and manufacturing organization (CDMO) services at current good manufacturing practices (cGMP) standards
HCATS opens of new manufacturing facility in New Jersey for cell and gene therapies. (Credit: PublicDomainPictures/Pixabay.)
Hitachi Chemical Advanced Therapeutics Solutions (HCATS) has opened its new cell and gene therapy manufacturing facility in Allendale, New Jersey.
HCATS is a subsidiary of Hitachi Chemical, representing its regenerative medicine business sector (RMBS) in North America. RMBS offers contract development and manufacturing organization (CDMO) services at current good manufacturing practices (cGMP) standards.
The company said that its new facility has been designed to address the needs of the commercial cell and gene therapy products and would double its existing manufacturing capacity in New Jersey.
HCATS president and CEO Robert Preti said: “The opening of this new facility marks an important milestone for HCATS and will offer a state-of-the-art resource for our clients as they commercialize cell and gene therapies.
“Access to this type of manufacturing space is needed across the industry to ensure the continued growth and momentum of these promising therapeutics. This facility will require up to 500 more employees to reach full operational capacity over the next several years, supporting our growing roster of clients.”
HCATS’ new facility to meet the needs of commercial cell and gene therapy products
The new facility is said to contain six classified environment rooms and is designed with a capacity to add more rooms with a specific configuration, to address the emerging client needs.
In addition, the new cell and gene therapy manufacturing facility includes advanced manufacturing development laboratories, quality control and microbiological laboratories, warehousing, executive offices and meeting space.
HCATS said that its investment in new facility expansion, quality systems and commercial expertise, is in line with its goal of meeting its commercial product manufacturing commitments.
New Jersey Governor Phil Murphy said: “I am excited for Hitachi Chemical Advanced Therapeutics Solutions’ future in New Jersey, and I have no doubt that their new, state-of-the-art facility will not only help New Jersey residents, but also contribute to expanding the innovation economy by bringing up to 500 new jobs to our state.
“With our highly educated and diverse workforce, New Jersey is the perfect location for expanding biotech firms like Hitachi Chemical.”